South East Asia New-born Screening Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

What is the South East Asia New-born Screening Market Size and Growth Rate?

• The South East Asia new-born screening market size was valued at USD 120 million in 2025 and is expected to reach USD 260. 42 million by 2033, at a CAGR of 10.17% during the forecast period
• This growth is driven by factors such as rising prevalence of congenital disorders, government mandates, and advancements in screening technologies

What are the Major Takeaways of New-born Screening Market?

• Newborn screening is a vital process that helps detect congenital disorders early, allowing for timely interventions that can significantly improve health outcomes for infants. It includes tests for metabolic, genetic, and hearing disorders, typically conducted shortly after birth
• The newborn screening market is experiencing steady growth, driven by rising awareness of the importance of early diagnosis, increased government mandates and healthcare initiatives, advancements in screening technologies, and the growing prevalence of congenital disorder
• Indonesia dominated the New-born Screening market with a 31.12% revenue share in 2025, driven by high birth rates, expanding public healthcare programs, and increasing government focus on neonatal health. Rising awareness and gradual implementation of screening initiatives are driving adoption
• Thailand is projected to register the fastest CAGR of 9.47% from 2026 to 2033, due to well-established healthcare infrastructure and government-supported screening programs. Increasing adoption of advanced screening technologies and strong public health initiatives support market expansion
• The Dried Blood Spot (DBS) Test segment dominated the market with a 48.6% share in 2025, owing to its widespread adoption for detecting multiple metabolic and genetic disorders such as PKU, cystic fibrosis, and sickle cell disease

Report Scope and New-born Screening Market Segmentation

What is the Key Trend in the New-born Screening Market?

“Increasing Prevalence of Congenital Illnesses”

• One prominent trend in the global newborn screening market is the increasing prevalence of congenital illnesses
• This trend is driven by the growing recognition of the importance of early detection, advancements in screening technologies, and rising healthcare awareness among parents and healthcare providers
• For instance, as the awareness around conditions such as sickle cell disease, cystic fibrosis, and phenylketonuria (PKU) grows, more governments and healthcare organizations are implementing mandatory newborn screening programs. These efforts aim to identify such disorders early and provide timely intervention
• The demand for newborn screening is expanding in developed markets, such as North America and Europe, and also in emerging markets, where rising healthcare access and infrastructure are improving early diagnostic capabilities
• As the focus on preventive healthcare continues to increase and more diseases are included in screening programs, the prevalence of congenital illnesses will such asly continue to shape the growth of the newborn screening market

What are the Key Drivers of New-born Screening Market?

• The rising awareness of the importance of early diagnosis is a significant driver for the newborn screening market, as healthcare providers focus on detecting conditions in infants at the earliest stages for better treatment outcome
• This awareness is gaining momentum worldwide, with increased support from governments, healthcare organizations, and advocacy groups aiming to enhance screening programs in both developed and developing regions.
• As healthcare systems evolve, there is a shift toward incorporating more comprehensive, cost-effective, and accurate newborn screening tests that can be seamlessly integrated into routine healthcare practices
• Companies are responding by developing advanced screening technologies that offer higher sensitivity, quicker results, and easier integration with existing healthcare infrastructures
• Furthermore, the rising focus on preventative healthcare and early interventions is propelling the adoption of newborn screening, with a particular emphasis on genetic and metabolic disorders
• Gentle Bio offers innovative diagnostic tools for newborn screening, focusing on genetic disorders and metabolic conditions, to align with the global push for comprehensive early diagnosis
• PerkinElmer provides integrated newborn screening platforms designed to support a wide range of tests, from blood and hearing screenings to more advanced genomic analyses
• As awareness and initiatives for early diagnosis continue to grow, the newborn screening market is expected to see sustained demand, driven by both public health policies and technological advancements in diagnostic capabilities

Which Factor is Challenging the Growth of the New-born Screening Market?

• Variations in screening practices pose a significant challenge for the newborn screening market, as inconsistent protocols and differing standards across regions complicate the implementation of universal screening program
• The need for standardized, reliable, and accessible newborn screening practices requires overcoming the disparities in healthcare infrastructure, training, and regulatory frameworks, leading to potential delays and gaps in screening coverage.
• Addressing these variations involves adapting screening technologies to meet the diverse needs of different regions, which can lead to higher costs and more complex implementation processes
• For instance, in countries with limited resources, screening practices may vary significantly, requiring tailored approaches to integrate advanced testing methods that balance affordability and diagnostic accuracy
• Without addressing these challenges through harmonization of practices, improved training, and global cooperation, the variability in newborn screening practices may limit the market’s growth and the overall effectiveness of early detection programs

How is the New-born Screening Market Segmented?

The market is segmented on the basis of test type, product type, technology, disease type, and end user.

• By Test Type

On the basis of test type, the new-born screening market is segmented into Dried Blood Spot Test, Hearing Screen Test, and Critical Congenital Heart Diseases (CCHD) Test. The Dried Blood Spot (DBS) Test segment dominated the market with a 48.6% share in 2025, owing to its widespread adoption for detecting multiple metabolic and genetic disorders such as PKU, cystic fibrosis, and sickle cell disease. DBS testing is cost-effective, minimally invasive, and suitable for large-scale screening programs, making it a standard method in national healthcare systems.

The CCHD Test segment is expected to grow at the fastest CAGR from 2026 to 2033, driven by increasing awareness of early cardiac diagnosis and rising implementation of mandatory screening policies. Advancements in pulse oximetry and improved accuracy in early detection of heart defects are further accelerating adoption. Growing government initiatives and healthcare investments continue to strengthen screening coverage globally.

• By Product Type

On the basis of product type, the market is segmented into Instrument, Consumables, Hearing Screening Instruments, and Pulse Oximeters. The Consumables segment dominated the market with a 44.2% share in 2025, driven by recurring demand for reagents, test kits, and filter papers used in large-scale screening programs. High testing volumes in hospitals and laboratories ensure continuous consumption, supporting steady revenue generation.

The Pulse Oximeters segment is expected to grow at the fastest CAGR from 2026 to 2033, fueled by increasing screening for critical congenital heart diseases and rising adoption of non-invasive diagnostic tools. Technological advancements, portability, and ease of use further enhance their adoption across healthcare facilities. Expansion of neonatal care units and government-supported screening programs continue to boost demand for both consumables and advanced screening devices.

• By Technology

On the basis of technology, the market is segmented into Tandem Mass Spectrometry, Hearing Screen Technology, Pulse Oximetry Screening Technology, Immunoassays and Enzymatic Assays, Electrophoresis, and DNA-Based Assays. The Tandem Mass Spectrometry segment dominated the market with a 41.3% share in 2025, due to its high accuracy, ability to detect multiple disorders simultaneously, and widespread use in metabolic screening. It remains the gold standard for newborn screening in developed healthcare systems.

The DNA-Based Assays segment is projected to grow at the fastest CAGR from 2026 to 2033, driven by advancements in genetic testing, increasing focus on early disease detection, and rising adoption of precision medicine. Growing investments in genomics, improved affordability of genetic tests, and expansion of screening panels are accelerating the adoption of advanced molecular technologies in newborn screening programs.

• By Disease Type

On the basis of disease type, the market is segmented into Critical Congenital Heart Diseases, New-Born Hearing Loss, Sickle Cell Disease, Phenylketonuria (PKU), Cystic Fibrosis (CF), Maple Syrup Urine Disease, and Others. The Phenylketonuria (PKU) segment dominated the market with a 36.9% share in 2025, as it is one of the most commonly screened metabolic disorders globally and is included in nearly all national newborn screening programs. Early detection enables effective dietary management, preventing severe complications.

The Critical Congenital Heart Diseases segment is expected to grow at the fastest CAGR from 2026 to 2033, driven by increasing awareness, improved screening technologies, and mandatory screening regulations in several countries. Rising incidence of congenital heart defects and advancements in non-invasive diagnostic tools are further supporting segment growth.

• By End User

On the basis of end user, the new-born screening market is segmented into Hospital, Paediatric Clinics, and Clinics. The Hospital segment dominated the market with a 57.4% share in 2025, attributed to the high number of births occurring in hospital settings, availability of advanced diagnostic infrastructure, and presence of skilled healthcare professionals. Hospitals serve as primary centers for conducting comprehensive newborn screening tests immediately after birth.

The Paediatric Clinics segment is projected to grow at the fastest CAGR from 2026 to 2033, driven by increasing follow-up screenings, rising outpatient care, and expanding access to specialized child healthcare services. Growing awareness among parents, improved healthcare accessibility, and expansion of neonatal care services are further accelerating demand across pediatric and clinical settings.

Which Region Holds the Largest Share of the New-born Screening Market?

• Indonesia dominated the New-born Screening market with a 31.12% revenue share in 2025, driven by high birth rates, expanding public healthcare programs, and increasing government focus on neonatal health. Rising awareness and gradual implementation of screening initiatives are driving adoption
• Rising healthcare awareness, improving medical infrastructure, and increasing public and private sector investments further support regional market development

Thailand New-born Screening Market Insight

Thailand is projected to register the fastest CAGR of 9.47% from 2026 to 2033, due to well-established healthcare infrastructure and government-supported screening programs. Increasing adoption of advanced screening technologies and strong public health initiatives support market expansion.

Malaysia New-born Screening Market Insight

Malaysia contributes significantly, driven by improving healthcare facilities, rising awareness of genetic disorders, and increasing adoption of early diagnostic practices. Government initiatives and private healthcare investments further boost growth.

Singapore New-born Screening Market Insight

Singapore represents a technologically advanced market, supported by high healthcare spending, strong regulatory frameworks, and early adoption of advanced screening technologies such as DNA-based assays and mass spectrometry.

Vietnam New-born Screening Market Insight

Vietnam is emerging as a growth market due to expanding healthcare access, rising birth rates, and increasing government focus on maternal and child health. Growing awareness campaigns and healthcare investments are accelerating adoption.

Philippines New-born Screening Market Insight

The Philippines contributes significantly with established national newborn screening programs and increasing awareness of early disease detection. Government support and improving healthcare infrastructure continue to drive market penetration.

Which are the Top Companies in New-born Screening Market?

The new-born screening industry is primarily led by well-established companies, including:

• PerkinElmer Inc., (U.S.)
• Demant A/S (Denmark)
• Natus Medical Incorporated (U.S.)
• Bio-Rad Laboratories (U.S.)
• Luminex Corporation (U.S.)
• F. Hoffmann-La Roche Ltd., (Switzerland)
• Thermo Fisher Scientific Inc., (U.S.)
• Bruker (U.S.)
• Danaher Corporation (U.S.)
• Medtronic (Ireland)
• Chromsystems Instruments & Chemicals GmbH (Germany)
• Trivitron Healthcare (India)
• Baebies Inc., (U.S.)

What are the Recent Developments in South East Asia New-born Screening Market?

• In April 2024, Revvity introduced a next-generation sequencing-based panel and workflow for newborn screening, aiming to enhance current screening programs that predominantly rely on biochemical testing, thereby positioning itself to significantly impact the market by offering more comprehensive and accurate diagnostic capabilities
• In December, Revvity launched its EONIS Q system, a CE-IVD declared platform that allows laboratories in countries accepting the CE marking to integrate molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns, potentially expanding the adoption of advanced molecular diagnostics and advancing the market for genetic newborn screening
• In September 2020, PerkinElmer, Inc., a worldwide company devoted to developing for a healthy society, has gained CE-IVD certification for their EONISTM newborn screening assay, which screens for SMA (spinal muscular atrophy), SCID (severe combined immunodeficiency), and XLA (X-linked agammaglobulinemia). This IVD RT-PCR assay is designed to interact with PerkinElmer's full newborn screening workflow, giving labs a complete, single-source solution that includes everything from sample to solution

SKU-17744